CN105408320B - 用于治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物 - Google Patents

用于治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物 Download PDF

Info

Publication number
CN105408320B
CN105408320B CN201480026333.XA CN201480026333A CN105408320B CN 105408320 B CN105408320 B CN 105408320B CN 201480026333 A CN201480026333 A CN 201480026333A CN 105408320 B CN105408320 B CN 105408320B
Authority
CN
China
Prior art keywords
substituted
compound
aryl
heterocycle
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480026333.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN105408320A (zh
Inventor
李嘉强
刘继峰
W·李
A·古比奥
H·罗格夫
K·坪井
Y·高梨
S·东条
T·儿玉
K·久保田
T·卡奈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1Globe Biomedical Co Ltd
Original Assignee
1Globe Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co Ltd filed Critical 1Globe Biomedical Co Ltd
Publication of CN105408320A publication Critical patent/CN105408320A/zh
Application granted granted Critical
Publication of CN105408320B publication Critical patent/CN105408320B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
CN201480026333.XA 2013-03-13 2014-03-13 用于治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物 Active CN105408320B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361780248P 2013-03-13 2013-03-13
US201361780263P 2013-03-13 2013-03-13
US61/780,248 2013-03-13
US61/780,263 2013-03-13
PCT/US2014/026498 WO2014160401A1 (en) 2013-03-13 2014-03-13 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer

Publications (2)

Publication Number Publication Date
CN105408320A CN105408320A (zh) 2016-03-16
CN105408320B true CN105408320B (zh) 2019-08-13

Family

ID=50639949

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480026333.XA Active CN105408320B (zh) 2013-03-13 2014-03-13 用于治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物

Country Status (14)

Country Link
US (2) US20160031888A1 (enExample)
EP (1) EP2970206A1 (enExample)
JP (2) JP6378308B2 (enExample)
KR (1) KR20150127249A (enExample)
CN (1) CN105408320B (enExample)
AU (2) AU2014243869A1 (enExample)
BR (1) BR112015022431A2 (enExample)
CA (1) CA2904152A1 (enExample)
HK (1) HK1220184A1 (enExample)
IL (1) IL240960A0 (enExample)
MX (1) MX2015011456A (enExample)
RU (2) RU2015143526A (enExample)
SG (2) SG10201806965XA (enExample)
WO (1) WO2014160401A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104876928B (zh) * 2015-05-07 2016-09-14 浙江司太立制药股份有限公司 7-氮杂吲哚啉-2-酮类化合物及其制备方法
JPWO2017026119A1 (ja) * 2015-08-10 2018-05-24 大日本住友製薬株式会社 ５−（チアゾール−４−イル）インドリン−２−オン誘導体の精製方法
KR102109869B1 (ko) * 2015-11-12 2020-05-13 영남대학교 산학협력단 7-아자인돌린-2-온 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 약학 조성물
CN105461705B (zh) * 2015-11-30 2018-04-10 中国医科大学 二苯并氮杂卓二酮类抗肿瘤化合物及其制备方法
WO2018005444A2 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
CN107698593A (zh) * 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN106432228A (zh) * 2016-09-06 2017-02-22 浙江司太立制药股份有限公司 含有4‑肟基‑1‑哌啶基片段的7‑氮杂吲哚啉‑2‑酮类化合物及其制备方法
CN106397436A (zh) * 2016-09-06 2017-02-15 浙江司太立制药股份有限公司 5‑溴‑7‑氮杂吲哚啉‑2‑酮类化合物及其制备方法
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
TWI779059B (zh) 2017-06-30 2022-10-01 財團法人工業技術研究院 化合物用於製備治療自體免疫神經疾病及/或神經退化性疾病之藥物的用途
CN110357878B (zh) * 2018-03-26 2022-04-12 武汉誉祥医药科技有限公司 1,3-二氢-2H-吡咯并[3,2-b]吡啶-2-酮衍生物及其医药用途
CN119954787A (zh) 2018-04-18 2025-05-09 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
US11919912B2 (en) 2018-05-21 2024-03-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
BR112021005086A2 (pt) 2018-09-18 2021-06-08 1Globe Biomedical Co., Ltd. tratamento para doença hepática gordurosa não alcoólica
US12390460B2 (en) * 2018-09-18 2025-08-19 1Globe Biomedical Co., Ltd. Treatment for obesity
WO2021003339A1 (en) * 2019-07-03 2021-01-07 The Regents Of The University Of Colorado, A Body Corporate Amp-activated protein kinase inhibitors and methods of making and using the same
US20230212120A1 (en) * 2020-05-29 2023-07-06 The Regents Of The University Of Michigan Small molecule inhibitors of grk5 and grk5 subfamily members and uses thereof
CN111675647B (zh) * 2020-06-26 2022-03-01 深圳技术大学 2-吲哚酮类pak1抑制剂及其在抗肿瘤治疗药物中的应用
JP7713619B2 (ja) * 2020-07-10 2025-07-28 ブロッサムヒル・セラピューティクス・インコーポレイテッド 大員環分子およびそれらの使用
MX2024008413A (es) * 2022-01-05 2024-09-17 Blossomhill Therapeutics Inc Compuestos macrocíclicos y uso como inhibidores de cinasas.
CN114213396B (zh) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 一种吲哚-2-酮类化合物及其制备方法与用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046196A1 (en) * 1999-12-21 2001-06-28 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
CN1330648A (zh) * 1998-12-17 2002-01-09 霍夫曼-拉罗奇有限公司 作为jnk蛋白质激酶抑制剂的4－芳基羟吲哚
CN1439005A (zh) * 2000-02-15 2003-08-27 苏根公司 吡咯取代的2－二氢吲哚酮蛋白激酶抑制剂
CN1898205A (zh) * 2003-10-24 2007-01-17 舍林股份公司 吲哚满酮衍生物及其在治疗疾病状态如癌症中的用途
CN101848908A (zh) * 2007-09-06 2010-09-29 波士顿生物医药公司 激酶抑制剂的组合物及其在治疗癌症和其它与激酶相关的疾病中的用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (enExample) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
WO1997013767A1 (de) * 1995-10-09 1997-04-17 Chemisch Pharmazeutische Forschungsgesellschaft Mbh Heterocyclisch substituierte 1-indolcarboxamide als cyclooxygenase-2 inhibitoren
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
AU2001270260A1 (en) * 2000-06-30 2002-01-14 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
CA2432114A1 (en) * 2000-12-20 2002-07-18 Sugen, Inc. 4-(hetero)aryl substituted indolinones
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
EP1828123A1 (en) * 2004-12-17 2007-09-05 Boehringer Ingelheim International GmbH Indolinones and their use as antiproliferative agents
WO2007005644A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
US20070032555A1 (en) 2005-07-01 2007-02-08 Concert Pharmaceuticals Inc. Novel aryloxyphenyl-propanamines
JP2009502961A (ja) 2005-07-29 2009-01-29 コンサート ファーマシューティカルズ インコーポレイテッド 新規な医薬組成物
JP5301991B2 (ja) 2005-07-29 2013-09-25 コンサート ファーマシューティカルズ インコーポレイテッド 新規なベンゾ［ｄ］［１，３］−ジオキソール誘導体
WO2007084391A2 (en) * 2006-01-18 2007-07-26 Amgen Inc. Thiazole compounds as protein kinase b ( pkb) inhibitors
CN101007801A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯取代的2－二氢吲哚酮衍生物、其制法与医药上的用途
CN101522026A (zh) * 2006-10-06 2009-09-02 Irm责任有限公司 蛋白激酶抑制剂及其应用方法
JP5492194B2 (ja) * 2008-05-13 2014-05-14 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としての縮合窒素含有ヘテロ環およびその組成物
UY32010A (es) * 2008-07-29 2010-02-26 Boehringer Ingelheim Int Nuevas indolinonas, composiciones conteniéndolas y aplicaciones
US9227962B2 (en) * 2013-03-13 2016-01-05 Boston Biomedical, Inc. Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
CN106132412A (zh) * 2014-01-27 2016-11-16 北京强新生物科技有限公司 治疗癌症的新方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1330648A (zh) * 1998-12-17 2002-01-09 霍夫曼-拉罗奇有限公司 作为jnk蛋白质激酶抑制剂的4－芳基羟吲哚
WO2001046196A1 (en) * 1999-12-21 2001-06-28 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
CN1439005A (zh) * 2000-02-15 2003-08-27 苏根公司 吡咯取代的2－二氢吲哚酮蛋白激酶抑制剂
CN1898205A (zh) * 2003-10-24 2007-01-17 舍林股份公司 吲哚满酮衍生物及其在治疗疾病状态如癌症中的用途
CN101848908A (zh) * 2007-09-06 2010-09-29 波士顿生物医药公司 激酶抑制剂的组合物及其在治疗癌症和其它与激酶相关的疾病中的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis and biological evaluation of 3-ethylidene-1,3-dihydro-indol-2-ones as novel checkpoint 1 inhibitors;Nan-Horng Lin, et al.;《Bioorganic & Medicinal Chemistry Letters》;20051018;第16卷;第421-426页 *

Also Published As

Publication number Publication date
AU2018233033A1 (en) 2018-10-11
US20190241569A1 (en) 2019-08-08
EP2970206A1 (en) 2016-01-20
US20160031888A1 (en) 2016-02-04
CN105408320A (zh) 2016-03-16
MX2015011456A (es) 2016-05-31
SG10201806965XA (en) 2018-09-27
WO2014160401A1 (en) 2014-10-02
IL240960A0 (en) 2015-11-30
SG11201507346PA (en) 2015-10-29
RU2015143526A (ru) 2017-04-19
RU2019104092A (ru) 2019-03-20
CA2904152A1 (en) 2014-10-02
BR112015022431A2 (pt) 2017-05-09
AU2014243869A1 (en) 2015-09-24
JP2016513656A (ja) 2016-05-16
KR20150127249A (ko) 2015-11-16
JP6378308B2 (ja) 2018-08-22
JP2018168187A (ja) 2018-11-01
HK1220184A1 (zh) 2017-04-28

Similar Documents

Publication Publication Date Title
CN105408320B (zh) 用于治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物
JP7672451B2 (ja) Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
CN114269735B (zh) 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
JP2016513656A5 (enExample)
CN111362966B (zh) 作为irak4抑制剂的二环杂环衍生物
CN114728926A (zh) 一种rock抑制剂及其制备方法和用途
AU2007218059A1 (en) Pyrrolidine derivatives as ERK inhibitors
US20190241550A1 (en) Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
CN113330009A (zh) 氮杂环化合物、其制备方法及用途
AU2010247212B2 (en) 5-membered heterocyclic compound cyclopenta[c]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof
WO2020192650A1 (zh) 酰胺类化合物制备方法及其在医药领域的应用
JP2023547522A (ja) がんの治療のためのＫＲａｓ阻害剤
US20210101899A1 (en) Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof
CN119585275A (zh) 恢复p53突变功能的化合物及其应用
WO2025078984A1 (en) Substituted tricyclic compounds as kras degraders
TW202502759A (zh) 化合物及其作為抗癌藥的用途
CN113121524A (zh) 杂环亚砜亚胺化合物及其中间体、制备方法和应用
CN117777197A (zh) 一类含磷化合物及其制备和应用
HK40049426A (en) Heterocyclic sulfoximine compound and intermediate thereof, preparation method therefor, and application thereof
CN120858099A (zh) Cdk抑制剂
HK40067854A (en) Rock inhibitor, preparation method therefor and use thereof
HK40032377A (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
HK40032377B (zh) 作为irak4抑制剂的二环杂环衍生物
CN111655713A (zh) Iap抑制剂及其在药物中的应用
HK1148529A1 (en) Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant